AES - DRS - Synexus Clinical Research US, Inc.
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Allaw, Mohammed A
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
10356
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Active, not recruiting
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
NCT06857955: A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Recruiting
2
380
US, RoW
Saline, QCZ484
Novartis Pharmaceuticals
Hypertension
12/26
12/27
Nalley, Jacque
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial

Recruiting
N/A
390
US
Active treatment, Sham
Viveve Inc.
Urinary Incontinence, Stress
12/22
12/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Allaw, Mohammed A
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Completed
3
1083
Europe, Canada, US, RoW
Placebo, lorundrostat Dose 1, lorundrostat Dose 2
Mineralys Therapeutics Inc.
Hypertension
12/24
01/25
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
10356
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Active, not recruiting
3
1400
Europe, Canada, US, RoW
lorundrostat, Placebo
Mineralys Therapeutics Inc.
Hypertension
12/25
12/26
NCT06857955: A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Recruiting
2
380
US, RoW
Saline, QCZ484
Novartis Pharmaceuticals
Hypertension
12/26
12/27
Nalley, Jacque
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4205
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
PURSUIT, NCT04720352: Prospective US Radiofrequency SUI Trial

Recruiting
N/A
390
US
Active treatment, Sham
Viveve Inc.
Urinary Incontinence, Stress
12/22
12/22

Download Options